Nurse Practitioner, Family · Phoenix, AZ
NPI
1386088649
Since 2013
Specialty
Nurse Practitioner, Family
Code 363LF0000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
9305 W Thomas Rd Ste 305
Phoenix, AZ, 85037
Phone (623) 478-8000
Groups this clinician bills Medicare through
Medicare paid, 2024
$62K
1,431 services
Medicare patients, 2024
369
Average age 72
Drug cost, 2024
$4.6M
3,609 prescriptions
Company payments, 2025
$3,356
From 22 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Craig A Wiggins was code 17003 (destruction skin lesion), 341 times for 60 patients. In total Craig A Wiggins billed 1,431 services in 40 codes, and Medicare paid $62K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-12-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 341 | 60 | $3.97 | $1,353 |
| 99213 Office E&M - Established | Office | 224 | 171 | $46.11 | $10K |
| 17110 Destruction Skin Lesion | Office | 163 | 137 | $57.65 | $9,396 |
| 99214 Office E&M - Established | Office | 146 | 95 | $74.05 | $11K |
| 17000 Destruction Skin Lesion | Office | 106 | 88 | $27.03 | $2,866 |
| 99203 Office E&M - New | Office | 87 | 87 | $52.94 | $4,605 |
| 11102 Skin Biopsy | Office | 63 | 58 | $46.72 | $2,943 |
| 99204 Office E&M - New | Office | 60 | 60 | $95.51 | $5,730 |
| 96372 Injection Administration | Office | 40 | 20 | $8.02 | $321 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 31 | 16 | $0.75 | $23.23 |
| 11900 Skin | Office | 22 | 15 | $32.30 | $711 |
| 17004 Destruction Skin Lesion | Office | 20 | 15 | $79.18 | $1,584 |
| 17111 Destruction Skin Lesion | Office | 16 | 13 | $51.31 | $821 |
| 12031 Wound Repair - All Levels | Office | 14 | 14 | $150.26 | $2,104 |
By year: 2022 $58K for 1,615 services; 2023 $61K for 1,698 services; 2024 $62K for 1,431 services.
Medicare prescription drug claims, 2024
In 2024, the drug Craig A Wiggins prescribed most often to Medicare patients was Clobetasol Propionate, with 732 prescriptions and refills. In total Craig A Wiggins wrote 3,609 Medicare prescriptions that cost $4.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Clobetasol Propionate Generic | 732 | 756 | 338 | $38K |
| Ketoconazole Generic | 534 | 569 | 200 | $7,774 |
| Doxycycline Hyclate Generic | 286 | 294 | 201 | $11K |
| Dupixent Syringe Dupilumab | 221 | 225 | 36 | $934K |
| Mupirocin Generic | 169 | 169 | 152 | $1,541 |
| Clindamycin Phosphate Generic | 168 | 171 | 62 | $6,526 |
| Otezla Apremilast | 111 | 111 | 16 | $578K |
| Tretinoin Generic | 99 | 107 | 47 | $7,879 |
| Triamcinolone Acetonide Generic | 84 | 101 | 45 | $1,288 |
| Humira(Cf) Pen Adalimumab | 77 | 78 | 11 | $648K |
| Terbinafine Hcl Generic | 73 | 73 | 39 | $766 |
| Dupixent Pen Dupilumab | 66 | 67 | 14 | $278K |
| Tacrolimus Generic | 61 | 61 | 42 | $5,525 |
| Methotrexate Methotrexate Sodium | 56 | 66 | 22 | $495 |
| Dutasteride Generic | 51 | 85 | 18 | $1,136 |
Brand drugs: 841 claims; generic drugs: 2,768 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Craig A Wiggins $3,356 ($3,356 in general payments such as food, travel and fees) from 22 companies. The largest payer was Genzyme Corporation with $417.
| Company | Payments | Amount |
|---|---|---|
| Genzyme Corporation SNY | 15 | $417 |
| Abbvie Inc. ABBV | 22 | $398 |
| Novartis Pharmaceuticals Corporation NVS | 24 | $359 |
| LEO Pharma Inc. | 6 | $277 |
| Incyte Corporation INCY | 16 | $267 |
| UCB, Inc. UCB.BR | 18 | $238 |
| Regeneron Healthcare Solutions, Inc. REGN | 10 | $228 |
| Organon LLC OGN | 11 | $188 |
| Galderma Laboratories, L.P. GALD.SW | 12 | $186 |
| Botanix SB Inc | 11 | $154 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.